Cerebral Palsy Clinical Trials

Find Cerebral Palsy Clinical Trials Near You

Smart Ankle-Foot Orthosis and 5-Azacitidine to Enhance Gait and Community Mobility for Children With Cerebral Palsy

Status: Recruiting
Location: See location...
Intervention Type: Device, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is an intervention study to investigate the impact of a smart ankle-foot orthosis (AFO) on mobility outcomes in children with Cerebral Palsy. Participants will complete a three phase protocol including 6-weeks of at home training with the smart AFO. Participants will also have the option to participate in a randomized control trial to investigate the impact of 5-Azacitidine combined with the smart AFO to further effect mobility outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 8
Maximum Age: 17
Healthy Volunteers: f
View:

• Diagnosis of cerebral palsy classified as Gross Motor Function Classification System (GMFCS) levels I to III

• Between 8 and 17 years and 8 months of age at the time of enrollment/consent. Participants that will turn 18 during the course of the study will not be included as pausing the at-home protocol until re-consenting is possible could interfere with intervention results.

• Stable medical condition as determined by the investigator.

• Adequate caregiver support to be able to participate in training and assessment sessions for the duration of the study, at the discretion of the PI.

• Height/weight/BMI between the 5th - 95th percentile of children with cerebral palsy

• Able to walk for at least 6 minutes (assisted or unassisted)

• Able to understand and follow simple directions

• Able to safely fit into a device configuration and tolerate assistance without knee hyperextension while walking

• At least 20 degrees of passive ankle plantar flexion range of motion

• Physician approval for participation

Locations
United States
Illinois
Shirley Ryan AbilityLab
RECRUITING
Chicago
Contact Information
Primary
Audrey Wiesner, BS
awiesner@sralab.org
3122388435
Backup
Jacklyn Stoller, PT, DPT
jstoller@sralab.org
3122387620
Time Frame
Start Date: 2026-05-28
Estimated Completion Date: 2030-08-31
Participants
Target number of participants: 60
Treatments
Experimental: Smart AFO & Home Intervention Training + 5-Azacitidine
Participants will receive one Smart AFO device for use during the at-home intervention phase of the study. Participants will be asked to complete and log at least three 30-minute gait training sessions per week at home with the device.~Each session will involve:~1. Walking for 5-10 minutes intervals for 3 trials, with the goal of performing at a 7/10 on the Pictorial Children's Effort Rating Table (PCERT)~2. Monitoring Heart Rate~3. Caregiver filling out brief log to track training session details.~A subset of opt-in participants will also be randomized to receive either 5-azacitidine (VIDAZA) or placebo (Mannitol) at midpoint. A registered nurse will deliver a single subcutaneous injection of either AZA or placebo at a dose of 75 mg/m² to the participants lower abdomen or medial thigh.
Active_comparator: Smart AFO & Home Intervention Training + Mannitol (Placebo)
Participants will receive one Smart AFO device for use during the at-home intervention phase of the study. Participants will be asked to complete and log at least three 30-minute gait training sessions per week at home with the device.~Each session will involve:~1. Walking for 5-10 minutes intervals for 3 trials, with the goal of performing at a 7/10 on the Pictorial Children's Effort Rating Table (PCERT)~2. Monitoring Heart Rate~3. Caregiver filling out brief log to track training session details.~A subset of opt-in participants will also be randomized to receive either 5-azacitidine (VIDAZA) or placebo (Mannitol) at midpoint. A registered nurse will deliver a single subcutaneous injection of either AZA or placebo at a dose of 75 mg/m² to the participants lower abdomen or medial thigh.
Active_comparator: Smart AFO & Home Intervention Training
Participants will receive one Smart AFO device for use during the at-home intervention phase of the study. Participants will be asked to complete and log at least three 30-minute gait training sessions per week at home with the device.~Each session will involve:~1. Walking for 5-10 minutes intervals for 3 trials, with the goal of performing at a 7/10 on the Pictorial Children's Effort Rating Table (PCERT)~2. Monitoring Heart Rate~3. Caregiver filling out brief log to track training session details.
Related Therapeutic Areas
Sponsors
Leads: Shirley Ryan AbilityLab

This content was sourced from clinicaltrials.gov